Johnson & Johnson (JNJ)

122.73
NYSE : Health Care
Prev Close 120.90
Day Low/High 120.90 / 122.74
52 Wk Low/High 105.04 / 126.07
Avg Volume 6.96M
Exchange NYSE
Shares Outstanding 2.72B
Market Cap 331.09B
EPS 6.10
P/E Ratio 20.52
Div & Yield 3.20 (2.60%)

Latest News

Cramer: When Someone Calls a Market Top, What's Their Motivation?

Cramer: When Someone Calls a Market Top, What's Their Motivation?

It's better to be early than wrong. Though being wrong isn't so awful.

Cramer: Buyers for Bristol-Myers Are Few and Far Between

Cramer: Buyers for Bristol-Myers Are Few and Far Between

Icahn may have a tough time finding interest in this behemoth.

Bristol-Myers Buys Back Shares, Shuffles Board

Bristol-Myers Buys Back Shares, Shuffles Board

The drug company will carry out 80% of a $2B repurchase by Feb. 28 after pressure from insurgent Jana Partners. Icahn also reportedly acquired a stake, with focus on M&A.

The Natural Food Craze Is Now Sweeping Into Personal Care Products

The Natural Food Craze Is Now Sweeping Into Personal Care Products

Demand for 'green' consumer products is rising and giants like Procter & Gamble are noticing.

Hurry Up and Grab Some Johnson & Johnson Before the Stock Bursts Even More

Hurry Up and Grab Some Johnson & Johnson Before the Stock Bursts Even More

This is what the charts say.

Health Care ETF Has Been Ailing

Health Care ETF Has Been Ailing

You might want to review your holdings in the sector.

Biotech Buoyed by Deal Talk

Biotech Buoyed by Deal Talk

M&A activity is in a serious upswing, and here are some names to watch.

Integra Scoops up JNJ's Codman Neurosurgery for $1.05 Billion

Integra Scoops up JNJ's Codman Neurosurgery for $1.05 Billion

Integra hopes this deal will grow its revenue to $2 billion sooner than expected.

Integra Scoops Up JNJ's Codman Neurosurgery for $1.05 Billion

Integra Scoops Up JNJ's Codman Neurosurgery for $1.05 Billion

The company hopes the JNJ assets will give revenue growth a boost.

Signs That Upside Is Limited Abound

But is more typical to get a 4% pullback from these sorts of readings than to see the market collapse.

Harley-Davidson: Cramer's Top Takeaways

Harley-Davidson: Cramer's Top Takeaways

Harley needs to keep expanding overseas and taking market share from the competition, says Jim Cramer.

Kratos Defense and Security Solutions: Cramer's Top Takeaways

Kratos Defense and Security Solutions: Cramer's Top Takeaways

Jim Cramer says Kratos is not too big, and not too small, but just the right size to benefit from increased defense spending.

Taser: Cramer's Top Takeaways

Taser: Cramer's Top Takeaways

Taser CEO Rick Smith tells Jim Cramer his company's acquisitions will add AI to its platform to help analyze data for law enforcement.

U.S. Steel, Universal Display, Bristol-Myers Squibb: 'Mad Money' Lightning Round

U.S. Steel, Universal Display, Bristol-Myers Squibb: 'Mad Money' Lightning Round

Jim Cramer is bullish on United States Steel and Universal Display, less so with Arconic and Himax Technologies.

Game Plan for the Week Ahead: Cramer's 'Mad Money' Recap (Friday 2/10/17)

Game Plan for the Week Ahead: Cramer's 'Mad Money' Recap (Friday 2/10/17)

Investors should keep an eye on interest rates and oil, but remember next week is still a week of big earnings reports, says Jim Cramer.

Why Dump Good Stocks?; Gamers, Oil and Industrials Take a Ride: Jim Cramer's Best Blog

Why Dump Good Stocks?; Gamers, Oil and Industrials Take a Ride: Jim Cramer's Best Blog

Jim Cramer ponders what makes people dump good stocks and discusses the ride gamers, oil and industrials took.

Cramer: Why Are People Dumping Such Good Stocks?

Cramer: Why Are People Dumping Such Good Stocks?

Amazon, J&J, IBM and others don't deserve this treatment.

Cramer: Like Them or Not (and I Don't), Bonds Set the Tone Today

Cramer: Like Them or Not (and I Don't), Bonds Set the Tone Today

They have become a referendum on Trump's plans for lower corporate taxes.

These Are the 5 Perfect Dividend Stocks for Today's Market

These Are the 5 Perfect Dividend Stocks for Today's Market

Abbott Labs is one of four names to own.

Trump's Executive Order Could Severely Damage Your Retirement Portfolio

Trump's Executive Order Could Severely Damage Your Retirement Portfolio

Here's how you can protect your savings.

Pfizer CEO: 'Misinformation About Drug Pricing Is Far Greater Than I've Ever Seen'

Pfizer CEO: 'Misinformation About Drug Pricing Is Far Greater Than I've Ever Seen'

The pharma giant will lever up should a strategic deal opportunity come along, too.

Acadia Pops on Takeout Rumors, But Don't Buy on M&A Just Yet

Acadia Pops on Takeout Rumors, But Don't Buy on M&A Just Yet

The company's shares jumped 5% midday Friday on rumors that Astrazeneca could buy Acadia.

Wall Street Ends January on Weak Note as Washington Division Deepens

Wall Street Ends January on Weak Note as Washington Division Deepens

It's day 12 in Trump's America and the shine of an outsider presidency has already worn off.

Dow Is On Track for Worst Day of 2017 Amid Trump White House Uncertainty

Dow Is On Track for Worst Day of 2017 Amid Trump White House Uncertainty

Deep political and civic division over recent executive actions from the White House continue to make market waves on Tuesday.

S&P 500 Falls for a Fourth Day as 'Rose-Tinted Glasses' of Trump Presidency Come Off

S&P 500 Falls for a Fourth Day as 'Rose-Tinted Glasses' of Trump Presidency Come Off

Uncertainty surrounding an immigration ban on a number of Muslim-majority countries continues to fuel volatility on markets on Tuesday.

TheStreet Quant Rating: A- (Buy)